Page last updated: 2024-08-24

valsartan and Apoplexy

valsartan has been researched along with Apoplexy in 48 studies

Research

Studies (48)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's20 (41.67)29.6817
2010's22 (45.83)24.3611
2020's6 (12.50)2.80

Authors

AuthorsStudies
Gu, J; Wang, CQ; Wang, Y; Zhang, JF1
Abraham, WT; Butt, JH; Desai, AS; Dewan, P; Dickstein, K; Ferreira, JP; Jhund, PS; Køber, L; McMurray, JJV; Packer, M; Petrie, MC; Rouleau, JL; Solomon, SD; Stewart, S; Swedberg, K; Zile, MR1
Adamsson Eryd, S; Bodegård, J; Bozkurt, B; Cleland, JGF; Khordoc, C; Kishi, T; Lund, LH; Savarese, G; Thuresson, M; Vardeny, O; Zhang, R1
Lee, YB; Shin, DH; Song, S1
McAlister, FA; Youngson, E1
Berge, E; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA; Wyller, TB1
Letizia, C; Petramala, L1
Berge, E; Hua, TA; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA1
Choi, MH; Hong, JM; Lee, JS; Lee, SE; Lee, SJ; Park, RW; Yoon, D1
Bianchi, F; Cotugno, M; Forte, M; Madonna, M; Marchitti, S; Rubattu, S; Stanzione, R; Volpe, M1
Califf, RM; Chiang, FT; Giles, TD; Haffner, SM; Holman, RR; Mazzone, T; McMurray, JJ; Preiss, D; Rutten, GE; Standl, E; Sun, JL; Thomas, LE; Tognoni, G1
Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K1
Califf, RM; Kober, L; Lewis, EF; Li, Y; Pfeffer, MA; Reed, SD; Rouleau, JL; Schulman, KA; Solomon, SD; Velazquez, EJ; Weinfurt, KP; White, HD1
Bae, HJ; Hong, KS; Kang, DW; Koo, J; Lee, BC; Lee, J; Oh, MS; Park, JM; Yu, KH1
Gröhn, O; Haapalinna, A; Haasio, K; Hyttilä-Hopponen, M; Kivikko, M; Kuoppamäki, M; Levijoki, J; Miettinen, R; Pollesello, P; Puoliväli, J; Sallinen, J; Tähtivaara, L; Yrjänheikki, J1
Alves, C; Carballo, S; Darbellay, P; Lebowitz, D; Moret, M; Sabeh, N1
Bangalore, S; Berge, E; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Mancia, G; Messerli, FH; Weber, MA; Zanchetti, A; Zappe, D1
Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Mancia, G; Weber, MA; Zanchetti, A; Zappe, DH1
Harumi Higuchi Dos Santos, M; Holman, RR; Lopes, RD; McMurray, JJ; Pieper, K; Sharma, A; Sun, JL1
Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tamamaki, N; Tokutomi, Y; Yamamoto, E1
Bethel, MA; Califf, RM; Haffner, SM; Holman, R; Hua, TA; Huntsman-Labed, A; McMurray, J1
Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B1
Hall, AS; Strauss, MH1
Eto, T; Imai, Y; Imaizumi, T; Ito, S; Kikuchi, K; Kimura, G; Matsuoka, H; Ogihara, T; Rakugi, H; Saruta, T; Shimada, K; Shimamoto, K; Takishita, S; Ueshima, H1
Hasegawa, H; Kobayashi, Y; Komuro, I; Kuwabara, Y; Mizuma, H; Narumi, H; Shindo, S; Takano, H1
Kimura, S; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H1
Koide, M; Matsubara, H; Sawada, T; Shiraishi, J; Yamada, H1
Brunner, HR; Hua, TA; Jia, Y; Julius, S; Kjeldsen, SE; Mancia, G; McInnes, GT; Schork, A; Weber, MA; Zanchetti, A; Zappe, DH1
Chujo, M; Hashimoto, T; Ishigaki, M; Kohro, T; Yamazaki, T1
Kanorskiĭ, SG; Shevelev, VI1
Isaka, N; Ito, M; Kaibuchi, K; Kongo, M; Kureishi, Y; Moriki, N; Nakakuki, T; Nakano, T; Okamoto, R; Seko, T1
Williams, B1
Banfi, C; Brioschi, M; Crippa, V; de Gasparo, M; Gelosa, P; Gianazza, E; Gianella, A; Guerrini, U; Nobili, E; Sironi, L; Tremoli, E1
Aguilar, D; Belenkov, YN; Califf, RM; Diaz, R; Francis, GS; Henis, M; Køber, L; Leimberger, JD; McMurray, JJ; O'Connor, CM; Pfeffer, MA; Rouleau, JL; Skali, H; Solomon, SD; Varshavsky, S; Velazquez, EJ1
Califf, R; Howlett, J; Køber, L; Maggioni, A; McMurray, J; Pfeffer, M; Pieper, K; Reed, S; Rouleau, J; Solomon, S; Swedberg, K; Van de Werf, F; Velazquez, E; White, H1
Chrysant, GS; Chrysant, SG1
Ebrahimian, T; Gratton, JP; He, Y; Savoia, C; Schiffrin, EL; Touyz, RM1
Victor, RG1
Califf, RM; Howlett, J; Kober, L; Maggioni, AP; McMurray, JJ; Pfeffer, MA; Rouleau, JL; Signorovitch, J; Solomon, SD; Thune, JJ; Velazquez, EJ; Zelenkofske, S1
Achard, JM; Boutitie, F; Fournier, A; Gueyffier, F; Temmar, M1
Rupp, H1
Amiri, F; Brassard, P; Iglarz, M; Javeshghani, DM; Pu, Q; Schiffrin, EL; Webb, RL1
Asai, S; Ishikawa, K; Nishida, Y; Sugahara-Kobayashi, M; Takahashi, Y1
Laverty, R; Ledingham, JM1
Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L1

Reviews

6 review(s) available for valsartan and Apoplexy

ArticleYear
Determining the most appropriate components for a composite clinical trial outcome.
    American heart journal, 2008, Volume: 156, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Data Collection; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Outcome Assessment, Health Care; Research Design; Stroke; Tetrazoles; Valine; Valsartan

2008
Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Minerva cardioangiologica, 2009, Volume: 57, Issue:6

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Middle Aged; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Saralasin; Secondary Prevention; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan

2009
VALUE and supremacy of blood pressure control for cardiovascular protection.
    Journal of hypertension, 2004, Volume: 22, Issue:8

    Topics: Antihypertensive Agents; Humans; Hypertension; Myocardial Infarction; Stroke; Tetrazoles; Valine; Valsartan

2004
The pleiotropic effects of angiotensin receptor blockers.
    Journal of clinical hypertension (Greenwich, Conn.), 2006, Volume: 8, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Diabetes Mellitus; Heart; Humans; Kidney; Losartan; Platelet Aggregation; Stroke; Tetrazoles; Uric Acid; Valine; Valsartan

2006
Pathophysiology of target-organ disease: does angiotensin II remain the key?
    Journal of clinical hypertension (Greenwich, Conn.), 2007, Volume: 9, Issue:11 Suppl 4

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Disease Progression; Humans; Hypertension; Losartan; Myocardial Infarction; Renin; Renin-Angiotensin System; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan

2007
Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
    Current medical research and opinion, 2007, Volume: 23 Suppl 5

    Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Catecholamines; Humans; Hypertension; Imidazoles; Norepinephrine; Stroke; Tetrazoles; Thiophenes; Valine; Valsartan

2007

Trials

14 trial(s) available for valsartan and Apoplexy

ArticleYear
Comparison of the Effect of Fimasartan versus Valsartan on Blood Pressure Variability in Acute Ischemic Stroke: A Double-Blind Randomized Trial.
    Cardiovascular therapeutics, 2019, Volume: 2019

    Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Brain Ischemia; Double-Blind Method; Humans; Prospective Studies; Pyrimidines; Republic of Korea; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valsartan

2019
Blood Pressure-Lowering Profiles and Clinical Effects of Angiotensin Receptor Blockers Versus Calcium Channel Blockers.
    Hypertension (Dallas, Tex. : 1979), 2020, Volume: 75, Issue:6

    Topics: Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Determination; Calcium Channel Blockers; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Risk Assessment; Stroke; Time; Valsartan

2020
Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial.
    Scientific reports, 2018, 01-24, Volume: 8, Issue:1

    Topics: Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Cerebrovascular Circulation; Double-Blind Method; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Pyrimidines; Stroke; Tetrazoles; Treatment Outcome; Valsartan

2018
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
    The American journal of cardiology, 2013, Dec-01, Volume: 112, Issue:11

    Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Female; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Proportional Hazards Models; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan

2013
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction).
    JACC. Heart failure, 2014, Volume: 2, Issue:2

    Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Bundle-Branch Block; Captopril; Death, Sudden, Cardiac; Drug Therapy, Combination; Female; Health Status; Heart Failure; Hospitalization; Humans; Male; Myocardial Infarction; Quality of Life; Recurrence; Stroke; Survivors; Tetrazoles; Treatment Outcome; Valine; Valsartan

2014
Modest blood pressure reduction with valsartan in acute ischemic stroke: a prospective, randomized, open-label, blinded-end-point trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:5

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Molecular Sequence Data; Nervous System Diseases; Outcome Assessment, Health Care; Prospective Studies; Stroke; Valsartan

2015
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
    Blood pressure, 2016, Volume: 25, Issue:2

    Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Coronary Artery Disease; Diastole; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Factors; Stroke; Systole; Treatment Outcome; Valsartan

2016
Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial.
    European heart journal, 2016, Mar-21, Volume: 37, Issue:12

    Topics: Aged; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Male; Myocardial Infarction; Risk Factors; Stroke; Treatment Outcome; Valsartan

2016
Determining the most appropriate components for a composite clinical trial outcome.
    American heart journal, 2008, Volume: 156, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Data Collection; Endpoint Determination; Humans; Myocardial Infarction; Odds Ratio; Outcome Assessment, Health Care; Research Design; Stroke; Tetrazoles; Valine; Valsartan

2008
Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study.
    Hypertension (Dallas, Tex. : 1979), 2010, Volume: 56, Issue:2

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Male; Medical History Taking; Patient Selection; Proportional Hazards Models; Reference Values; Stroke; Systole; Tetrazoles; Valine; Valsartan

2010
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
    Journal of human hypertension, 2012, Volume: 26, Issue:11

    Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Cause of Death; Creatinine; Death, Sudden; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan

2012
Combination effect of calcium channel blocker and valsartan on cardiovascular event prevention in patients with high-risk hypertension: ancillary results of the KYOTO HEART Study.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2012, Volume: 34, Issue:2

    Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Female; Heart Failure; Humans; Hypertension; Japan; Male; Middle Aged; Myocardial Infarction; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan

2012
Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study).
    The American journal of cardiology, 2012, May-01, Volume: 109, Issue:9

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Incidence; Japan; Male; Prospective Studies; Risk Factors; Stroke; Survival Rate; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan

2012
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
    Journal of hypertension, 2012, Volume: 30, Issue:11

    Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Prognosis; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan

2012

Other Studies

29 other study(ies) available for valsartan and Apoplexy

ArticleYear
The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    European journal of internal medicine, 2023, Volume: 112

    Topics: Angiotensin Receptor Antagonists; Biphenyl Compounds; Brain Ischemia; Drug Combinations; Heart Failure; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Prospective Studies; Stroke; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2023
Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM-HF and ATMOSPHERE.
    European journal of heart failure, 2023, Volume: 25, Issue:5

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atmosphere; Biphenyl Compounds; Comorbidity; Drug Combinations; Heart Failure; Humans; Hypertension; Multimorbidity; Stroke; Stroke Volume; Tetrazoles; Valsartan

2023
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION HF.
    JACC. Heart failure, 2023, Volume: 11, Issue:10

    Topics: Adrenergic beta-Antagonists; Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Glucose; Heart Failure; Hospitalization; Humans; Longitudinal Studies; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Peripheral Arterial Disease; Renal Insufficiency, Chronic; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Stroke; Stroke Volume; United States; Valsartan

2023
Impact of the Generic Valsartan Recall in Alberta, Canada.
    Journal of the American College of Cardiology, 2020, 04-21, Volume: 75, Issue:15

    Topics: Aged; Alberta; Antihypertensive Agents; Carcinogens; Databases, Factual; Dimethylnitrosamine; Drug Recalls; Drug Substitution; Drugs, Generic; Emergency Service, Hospital; Humans; Hypertension; Office Visits; Stroke; Valsartan

2020
Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan).
    European heart journal. Cardiovascular pharmacotherapy, 2020, 07-01, Volume: 6, Issue:4

    Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Anticoagulants; Atrial Fibrillation; Biphenyl Compounds; Cardiology; Drug Combinations; Humans; Neprilysin; Stroke; Tetrazoles; Valsartan

2020
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.
    European heart journal, 2018, 06-21, Volume: 39, Issue:24

    Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Mortality; Myocardial Infarction; Prognosis; Proportional Hazards Models; Stroke; Valsartan

2018
Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
    Journal of hypertension, 2018, Volume: 36, Issue:9

    Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Cyclic GMP; Drug Combinations; Hypertension; Male; Neprilysin; Proteinuria; Rats; Rats, Inbred SHR; Stroke; Tetrazoles; Valsartan

2018
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
    Stroke, 2013, Volume: 44, Issue:9

    Topics: Aged; Antihypertensive Agents; Comorbidity; Controlled Clinical Trials as Topic; Cyclohexanes; Drug Therapy, Combination; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Male; Middle Aged; Nateglinide; Outcome Assessment, Health Care; Phenylalanine; Predictive Value of Tests; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan

2013
Clinical trial rigging: again!
    Prescrire international, 2014, Volume: 23, Issue:148

    Topics: Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Humans; Hypertension; Retraction of Publication as Topic; Scientific Misconduct; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan

2014
Levosimendan alone and in combination with valsartan prevents stroke in Dahl salt-sensitive rats.
    European journal of pharmacology, 2015, Mar-05, Volume: 750

    Topics: Animals; Blood Pressure; Blood Volume; Brain; Drug Interactions; Hydrazones; Male; Pyridazines; Rats; Rats, Inbred Dahl; Simendan; Stroke; Valsartan; Vasodilator Agents

2015
[Internal medicine in the hospital setting].
    Revue medicale suisse, 2015, Jan-21, Volume: 11, Issue:458

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Asymptomatic Diseases; Atrial Fibrillation; Biphenyl Compounds; Carotid Stenosis; Colchicine; Diuretics; Drug Combinations; Heart Failure; Hospitals; Humans; Internal Medicine; Liver Cirrhosis; Narcotics; Neprilysin; Pericarditis; Peritonitis; Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Spironolactone; Stroke; Tetrazoles; Valsartan

2015
International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
    Journal of the American Heart Association, 2017, 01-13, Volume: 6, Issue:1

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Asia; Australia; Cardiovascular Diseases; Cyclohexanes; Diabetes Mellitus, Type 2; Europe; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Incidence; Latin America; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Nateglinide; New Zealand; North America; Outcome Assessment, Health Care; Phenylalanine; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; South Africa; Stroke; Valsartan

2017
Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation.
    Stroke, 2008, Volume: 39, Issue:11

    Topics: Acetophenones; Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Astrocytes; Blood Pressure; Cerebral Cortex; Enzyme Activation; Enzyme Inhibitors; Humans; Hydralazine; Hypertension; Inflammation; Male; NADPH Oxidases; Neurons; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Sodium Chloride; Stroke; Tetrazoles; Valine; Valsartan

2008
Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study.
    European heart journal, 2010, Volume: 31, Issue:2

    Topics: Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension; Stroke; Tetrazoles; Valine; Valsartan

2010
The occurrence rate of cerebrovascular and cardiac events in patients receiving antihypertensive therapy from the post-marketing surveillance data for valsartan in Japan (J-VALID).
    Hypertension research : official journal of the Japanese Society of Hypertension, 2013, Volume: 36, Issue:2

    Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Female; Health Surveys; Heart Failure; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Myocardial Infarction; Product Surveillance, Postmarketing; Prospective Studies; Registries; Retrospective Studies; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan

2013
[Antihypertensive therapy and dynamics of vascular wall rigidity in elderly patients with non-valvular atrial fibrillation].
    Klinicheskaia meditsina, 2012, Volume: 90, Issue:9

    Topics: Aged; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Arterial Pressure; Arteries; Atrial Fibrillation; Combined Modality Therapy; Drug Monitoring; Female; Fluorobenzenes; Humans; Hypertension; Male; Myocardial Infarction; Perindopril; Pulse Wave Analysis; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Tetrazoles; Treatment Outcome; Ultrasonography, Doppler, Duplex; Valine; Valsartan; Vascular Resistance

2012
[Fixed combination of AT1 blocker and diuretic. Stroke preventive combination for hypertension].
    MMW Fortschritte der Medizin, 2002, Jul-11, Volume: 144, Issue:27-28

    Topics: Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Stroke; Tetrazoles; Treatment Outcome; Valine; Valsartan

2002
[AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
    MMW Fortschritte der Medizin, 2003, Apr-10, Volume: 145, Issue:15

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diuretics; Double-Blind Method; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Losartan; Meta-Analysis as Topic; Placebos; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors; Stroke; Tetrazoles; Time Factors; Valine; Valsartan

2003
RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2004, Volume: 27, Issue:4

    Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Cells, Cultured; Cyclic AMP; Cyclic GMP; Hypertension; Muscle, Smooth, Vascular; Prazosin; Rats; Rats, Inbred SHR; Rats, Inbred WKY; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Stroke; Tetrazoles; Valine; Valsartan

2004
Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall.
    The Journal of pharmacology and experimental therapeutics, 2004, Volume: 311, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Blood Pressure; Body Weight; Brain; Chemokine CCL2; Immunohistochemistry; Interleukin-1; Kidney; Magnetic Resonance Imaging; Male; Proteinuria; Rats; Rats, Inbred SHR; RNA, Messenger; Stroke; Survival Analysis; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan

2004
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Circulation, 2004, Sep-21, Volume: 110, Issue:12

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cohort Studies; Comorbidity; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Life Tables; Male; Medical Records; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left

2004
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Journal of the American College of Cardiology, 2006, Feb-21, Volume: 47, Issue:4

    Topics: Aged; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Captopril; Cardiovascular Diseases; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Recurrence; Stroke; Tetrazoles; Valine; Valsartan

2006
Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase.
    Journal of hypertension, 2006, Volume: 24, Issue:12

    Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cyclic GMP-Dependent Protein Kinases; Hypertension; Nitric Oxide; Rats; Receptors, Angiotensin; Stroke; Tetrazoles; Valine; Valsartan; Vasodilation

2006
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
    Hypertension (Dallas, Tex. : 1979), 2008, Volume: 51, Issue:1

    Topics: Aged; Antihypertensive Agents; Blood Pressure; Captopril; Cardiovascular Diseases; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Prognosis; Risk Factors; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2008
The JIKEI trial.
    Lancet (London, England), 2007, Dec-01, Volume: 370, Issue:9602

    Topics: Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Japan; Randomized Controlled Trials as Topic; Stroke; Tetrazoles; Valine; Valsartan

2007
Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
    Journal of hypertension, 2008, Volume: 26, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Endomyocardial Fibrosis; Endothelium, Vascular; Hydralazine; Hypertension; Male; Mesenteric Arteries; Neprilysin; Rats; Rats, Inbred SHR; Rats, Wistar; Stroke; Tetrazoles; Tyrosine; Valine; Valsartan

2008
Decreased expression of angiotensin II type 1 and type 2 receptors in the brain after long-term administration of antihypertensive drugs in stroke-prone spontaneously hypertensive rat.
    Journal of pharmacological sciences, 2008, Volume: 106, Issue:4

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Brain Stem; Calcium Channel Blockers; Cerebral Cortex; Disease Models, Animal; Down-Regulation; Enalapril; Hypertension; Male; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Stroke; Tetrazoles; Time Factors; Valine; Valsartan

2008
Basilar artery remodelling in the genetically hypertensive rat: effects of nitric oxide synthase inhibition and treatment with valsartan and enalapril.
    Clinical and experimental pharmacology & physiology, 2000, Volume: 27, Issue:8

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Basilar Artery; Blood Pressure; Brain; Enalapril; Enzyme Inhibitors; Hypertension; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Rats; Rats, Inbred SHR; Stroke; Tetrazoles; Valine; Valsartan; Ventricular Function, Left

2000
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
    Journal of cardiovascular pharmacology, 2001, Volume: 37, Issue:4

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Platelets; Blood Pressure; Humans; Hypertension; Losartan; P-Selectin; Platelet Activation; Platelet Adhesiveness; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Tetrazoles; Thromboxane A2; Valine; Valsartan

2001